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Abstract 
Background: The purpose of this study was to analyze the evolution of vascular, cardiac and renal target organ dam‑
age (TOD) in patients with increased insulin resistance over a 3.5 year follow‑up and to investigate gender difference 
and factors that influence its progression.
Methods: We performed a prospective observational study involving 112 patients (71 men, 41 women) who were 
followed for 3.5 years. Measurements included blood pressure, blood glucose, lipids, smoking, body mass index (BMI) 
and HOMA‑Ir Vascular TOD included carotid intima‑media thickness (IMT), pulse wave velocity (PWV) and ankle/bra‑
chial index (ABI). Cardiac TOD included Cornell voltage‑duration product and Sokolow. Renal TOD included creatinine, 
glomerular filtration and albumin/creatinine ratio.
Results: The IMT increased in both genders. Each year, the IMT increased 0.005 mm in men and 0.011 in women and 
the PWV 0.024 and 0.020 m/sec, respectively. The highest increase was in women with type 2 diabetes mellitus, who 
had an increase in TOD carotid (40 %), PWV (24 %) and renal TOD (20 %). Multiple regression analysis, after adjusting 
for age and gender, showed a negative association between duration since diabetes diagnosis and ABI (β = −0.006; 
p = 0.017) and between BMI and glomerular filtration (β = −0.813; p = 0.014). HbA1c was positively associated with 
PWV (β = 0.501; p = 0.014).
Conclusions: This study showed that the progression of vascular and renal TOD differs by gender. The increase in 
vascular and renal TOD was higher in women, especially in diabetic women. The PWV increase showed a positive 
association with mean HbA1c levels during the follow‑up. Glomerular filtration was associated with BMI and the ABI 
was associated with duration since type 2 diabetes mellitus diagnosis.
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Background
Cardiovascular disease (CVD) morbidity and mortality is 
greater in people with increased insulin resistance [(type 
2 diabetes mellitus (T2DM) or metabolic syndrome 
(MetS)] [1–3]. The presence of vascular [4–6], cardiac 
[7] and renal [8, 9] target organ damage (TOD) increases 
the risk of cardiovascular complications independent 
of the existing estimated risk [10]. In the general popu-
lation the overall median age for evident CVD is about 
9 years lower in men than in their women counterparts 
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worldwide [11], except in diabetic women who have a 
higher risk of CVD than diabetic men [12].
In the general population, left ventricular hypertrophy 
(LVH) is more prevalent in men [13] and peripheral arte-
rial disease is more prevalent in women [14]. However, 
carotid intima-media thickness (IMT) and pulse wave 
velocity (PWV) are higher in men, although this differ-
ence is attenuated with age [15]. Measurement of IMT 
increases the capacity to identify individuals with dia-
betes [16] or MetS [17] who are at a high risk of devel-
oping cardiovascular disease. Measurement of PWV 
increases the capacity to identify individuals with dia-
betes [16] or glucose intolerance [18], healthy individu-
als [19] and subjects with moderate or intermediate risk 
[20] who are at a high risk of developing cardiovascular 
disease. Patient age and gender are the most important 
determinants of IMT [21]. In the general population, the 
mean estimates of IMT progression ranged from 0.001 to 
0.030 mm per year for the common carotid artery IMT, 
the mean estimates of IMT progression ranged from 
0.001 to 0.030  mm per year for common carotid artery 
IMT, decreasing with control of the risk factors in dia-
betic individuals [22]. Postprandial blood glucose and 
HbA1c have a greater influence upon IMT than basal 
blood glucose [23], but there was no association to car-
diovascular events [24]. The predictors of PWV include 
abdominal obesity, hyperglycemia and dyslipidemia [15]. 
It has also been reported that adequate glucose and blood 
pressure control decreases the PWV progression in dia-
betic patients [25].
In diabetic men, albuminuria occurs more frequently 
and with a greater reduction in glomerular filtration rate 
than in diabetic women [26, 27], but LVH is more preva-
lent in diabetic women than in diabetic men [25].
However, differences in the evolution of the TOD 
between T2DM and MetS have been little studied [28], 
and the role that the gender plays in vascular, cardiac and 
renal TOD in patients with increased insulin resistance, 
remains unclear and there have been few longitudinal 
studies.
Therefore, we analyzed the evolution of vascular, car-
diac and renal TOD in patients with increased insulin 
resistance over a 3.5-year follow-up and investigated 




A prospective observational study was performed 
in a primary care setting, with a median of fol-
low up of 3.5  years (range, 2.9–3.9  years). This study 
included 112 subjects from the LOD-DIABETES study 
(NCT01065155) [29].
Study population
Using consecutive sampling, we included 112 patients 
with increased insulin resistance considering clinical 
criteria, i.e. with diagnosis of T2DM (n  =  68) or MetS 
(n = 44). Type 2 diabetes mellitus (T2DM) defined using 
the American Diabetes Association criteria [30] or MetS 
defined according to the National Cholesterol Education 
Program, ATP III [31]. The study included patients with 
diabetes or metabolic syndrome, who visited their family 
physician between January 2009 and January 2010, and 
these patients included 71 men (63.4 %) and 41 women 
(36.6  %). Exclusion criteria were as follows: patients 
who were unable to comply with the protocol require-
ments (psychological and/or cognitive disorders; failure 
to cooperate; educational limitations and problems in 
understanding written language; and failure to sign the 
informed consent document). Patients participating in a 
clinical trial during the study were also excluded, as were 
patients with serious life-threatening comorbidities in 
the previous 12 months.
The sample size was estimated to detect a statistically 
significant difference in the carotid IMT that was greater 
than or equal to 0.03  mm between baseline and the 
fourth assessment. Accepting an alpha risk of 0.05 and 
a beta risk of 0.2 in a two-sided test, 112 subjects were 
necessary to achieve a statistically significant difference. 
The standard deviation was estimated to be 0.11  mm, 
and the drop-out rate was estimated as 5  %. An inde-
pendent ethics committee of Salamanca Health Area 
(Spain) approved the study. All participants gave written 
informed consent, according to the general recommen-
dations of the Declaration of Helsinki [32].
Measurements
A detailed description has been published elsewhere of 
how clinical data were collected, including anthropomet-
ric measurements, blood pressure and TOD assessment 
[29].
Blood pressure
Three measurements of systolic (SBP) and diastolic blood 
pressure (DBP) were collected using a validated OMRON 
model M7 sphygmomanometer (Omron Health Care, 
Kyoto, Japan). We used the average of the last two meas-
urements according to the recommendations of the Euro-
pean Society of Hypertension [33]. Mean blood pressure 
(MBP) was calculated as the sum of SBP  +  2  ×  DBP, 
divided by 3.
Vascular assessment
Carotid femoral pulse wave velocity
PWV was estimated using the SphygmoCor System 
(AtCor Medical Pty Ltd., Head Office, West Ryde, 
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Australia), with patients in the supine position. The pulse 
wave of the carotid and femoral arteries were analyzed 
to estimate the ECG wave delay and calculate the PWV. 
Distance measurements from the sternal notch to the 
carotid and femoral arteries at the sensor location were 
collected using a measuring tape and multiplied by 0.8, as 
recommended by expert consensus [34]. TOD was indi-
cated if the PWV was greater than 10 m/sec [33].
Carotid intima media thickness
Carotid ultrasound to assess carotid IMT was performed 
by two investigators trained for this purpose before start-
ing the study. A Sonosite Micromax ultrasound (Son-
osite Inc., Bothell, Washington, USA) device paired with 
a 5–10  MHz multi-frequency high-resolution linear 
transducer with Sonocal software was used for auto-
matic measurement of IMT to optimize reproducibil-
ity. Common carotid artery measurements were made 
after examining a 10-mm longitudinal section 1 cm from 
the bifurcation. Measurements were performed at the 
proximal and distal wall in the lateral, anterior and pos-
terior projections. They followed an axis perpendicular 
to the artery to discriminate between two lines: one for 
the intima-blood interface and the other for the media-
adventitious interface. A total of 6 measurements were 
obtained for the right carotid and 6 measurements for the 
left carotid. We used the average values (average IMT) 
that were automatically calculated using the software 
[35]. The measurements were obtained with the subject 
lying down, with their head extended and slightly turned 
opposite of the carotid artery under study. Average IMT 
values were considered abnormal if they were >0.90 mm, 
if there were atherosclerotic plaques with a diameter of 
1.5 mm or if there was a focal increase of 0.5 mm or 50 % 
of the adjacent IMT [33].
Evaluation of peripheral artery involvement
Peripheral artery involvement was assessed using the 
ankle-brachial index (ABI) and was calculated in the 
morning for patients who had not drank coffee or smoked 
tobacco for at least 8  h prior to the measurement. The 
room temperature was 22–24  °C. Patients were supine 
with the feet uncovered. The pressure in the lower limbs 
was measured after resting for 20  min using a portable 
Watch BP Office for assessing the ABI (Microlife AG 
Swiss Corporation Espenstrasse 139; CH-9443 Widnau/
Switzerland). The ABI was calculated automatically for 
each foot by dividing the higher of the two systolic pres-
sures in the ankle by the higher of the two systolic pres-
sures in the arm. An ABI < 0.9 was considered abnormal 
[33].
Renal assessment
Kidney damage was assessed by measuring creatinine 
plasma concentration and glomerular filtration rate 
(eGFR) as estimated according to the Modification of 
Diet in Renal Disease-Isotopic Dilution Mass Spectrom-
etry (MDRD-IDMS) [36]. Proteinuria was assessed by 
the albumin/creatinine ratio, (performing a measure-
ment every year), following the 2013 European Society 
of Hypertension/European Society of Cardiology Guide-
lines criteria. TOD was defined as a plasma creatinine 
of 1.3  mg per 100  ml or higher in men and 1.2  mg per 
100 ml or higher in women and an eGFR below 60 ml per 
min or albumin/creatinine ratio ≥30 mg/g [33].
Cardiac assessment
The electrocardiographic examination was performed 
using a General Electric MAC 3.500 ECG System (Gen-
eral Electric, Niskayuna, NY, USA) that automatically 
measures the voltage and duration of waves and esti-
mates the criteria of the Cornell voltage–duration prod-
uct (Cornell VDP) and Sokolow Lyon product [37]. The 
TOD was defined according to the 2013 European Soci-
ety of Hypertension/European Society of Cardiology 
Guidelines criteria [33].
Laboratory determinations
Venous blood sampling was performed between 08:00 
and 09:00 after the individuals had fasted and abstained 
from smoking and the consumption of alcohol and caf-
feinated beverages for the previous 12 h. Fasting plasma 
glucose, HbA1c, homeostasis model assessment-insulin 
resistance (HOMA-IR), creatinine, total cholesterol, 
triglycerides and high-density lipoprotein (HDL) cho-
lesterol concentrations were measured using standard 
enzymatic automated methods. Low-density lipoprotein 
(LDL) cholesterol was estimated using the Friedewald 
equation. The atherogenic index was estimated by total 
cholesterol/HDL cholesterol.
The average annual increase in TOD was estimated by 
dividing the difference between the final and baseline 
evaluations by the years of follow-up. The individuals 
performing the various tests were blinded to the clinical 
data. All assessments were made within 10 days.
Statistics
Continuous variables were expressed as the 
mean ± standard deviation for normally distributed con-
tinuous data, the median (interquartile range, IQR) for 
asymmetrically distributed continuous data and the fre-
quency distribution for categorical data. Statistical nor-
mality was tested using the Kolmogorov–Smirnov test. 
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The Student’s t test was used to analyze the difference 
between quantitative variables by gender. The evolution 
of quantitative variables was analyzed using an analysis of 
variance for repeated measures, corrected by the Bonfer-
roni method. The presence or absence of sphericity was 
taken into account and the Greenhouse and Geisser cor-
rection was performed.
We used the McNemar and Cochran tests to contrast 
the hypothesis of two or more related proportions. In 
addition, we have analyzed the differences in the yearly 
increase in intima-media thickness (IMT), PWV and esti-
mated glomerular filtration rate (eGFR) in the group of 
diabetic individuals according to gender. We performed 
a multiple linear regression analysis, which was adjusted 
for age and gender, using the stepwise method, one for 
each of the dependent variable and differences between 
the fourth measure and baseline (IMT, ABI, cf-PWV, 
eGFR, Cornell VDP). The independent variables included 
were: years since diagnosis of diabetes, smoker and 
mean values taken at the four visits during the 3.5 years 
of follow-up (atherogenic index, mean blood pressure, 
body mass index, HbA1C, HOMA-IR, mean number of 
antihypertensive, lipid lowering and antidiabetic drugs). 
Data were analyzed using the SPSS version 20.0 statisti-
cal package (SPSS Inc., Chicago, Illinois, USA). A value of 
p < 0.05 was considered statistically significant.
Results
In the first year of follow-up, two men died as result of 
acute myocardial infarction. Subsequently, two non-fatal 
cardiovascular events occurred in the male group. In the 
female group, there was a non-fatal cardiovascular event. 
The flow chart is shown in Fig. 1.
The median time from diagnosis of type 2 diabetes mel-
litus was 9.20 ± 4.16 years. At baseline, the 60.9 % of men 
and 61.0 % of women had diabetes; 39.1 and 39.0 % had 
metabolic syndrome; 79.7 and 90.2 % had hypertension; 
78.3 and 75.6  % had dyslipidemia and 55.1 and 53.7  % 
were obese. The mean age was 61 ± 11 years in men and 
62 ± 12 in women. We found no statistical differences for 
gender in any risk factors evaluated.
Table  1 shows the cardiovascular risk factors, bio-
chemical data and drugs analyzed at each of the four 
evaluations by gender. Table  2 shows the basal and the 
annual assessments of vascular, cardiac and renal TOD 
by gender. In men, we observed an increase in IMT in the 
fourth assessment. In woman, we observed an increase in 
IMT and in the number of plaques.
Each year in men and women, the IMT increased 
0.005  mm and 0.011, the PWV increased 0.024 and 
0.020 m/sec and the eGFR increased -2.35 and 4.02 mL/
min/1.73  m, respectively. The highest increase was in 
women with type 2 diabetes mellitus (Table 3).
Figure  2 shows the trend and the percentage of par-
ticipants, by gender, who had vascular, cardiac and 
renal TOD at each of the four time points. The over-
all TOD increased in men and women by 10 and 17  %, 
respectively. In men and women, the overall vascular 
TOD increased by 11.5 and 14 %, the overall renal TOD 
increased by −8 and 7  %, and the overall cardiac TOD 
increased by 1.5 and 5 %, respectively.
Multiple regression analysis, using the Stepwise 
method, was performed after adjusting for age and gen-
der, and it showed a negative association between the 
duration since diagnosis of diabetes and ABI changes dur-
ing the follow up (β = −0.006; p = 0.017), and between 
the BMI and glomerular filtration changes (β = −0.813; 
p =  0.014). The HbA1c was positivenly associated with 
PWV changes (β = 0.501; p = 0.014; Table 4).
Discussion
This study included a 3.5-year median follow-up period 
of patients with increased insulin resistance, and it 
showed five important findings: (1) increased carotid 
TOD was higher in women; (2) increased renal TOD 
was higher in women and eGFR had a negative associa-
tion with BMI; (3) the largest increase in IMT, PWV and 
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Fig. 1 Study flow chart. The subjects analyzed each year are pre‑
sented in the flow chart. Additional information includes cardiovascu‑
lar events in each group and evaluation of patients by gender
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Table 1 Changes in cardiovascular risk factors and medications used by gender
Data for qualitative variables are expressed as n: number (%) and quantitative variables as mean ± standard deviation
BMI body mass index, LDL low density lipoprotein, HDL high density lipoprotein, HbA1C glycosylated hemoglobin, HOMA-IR homeostasis model assessment insulin 
resistance, SBP systolic blood pressure, DBP diastolic blood pressure
p < 0.05: between * baseline and 1st year; †baseline and 2nd year; ‡ baseline and 3rd year
p < 0.05: between §1st and 2nd year; ||1st and 3rd year
p < 0.05 between ¶2nd and 3rd year
Baseline (n=71) 1st year (n=69) 2nd y (n=69) 3rd y (n=69) p
Men
 Smoker’s, n (%)†‡§|| 20 (29) 20 (29) 14 (20) 14 (20) <0.001
 Ischemic heart disease n (%) 8 (11) 8 (12)  9 (13) 9 (13) 1.00
 Cerebrovascular disease n (%) 2 (3) 2 (3) 2 (3) 3 (4) 0.392
 BMI (kg/m2) 30.0 ± 4.1 30.3 ± 4.2 30.4 ± 4.4 30.3 ± 4.5 0.526
 Total cholesterol (mg/dL)‡ 198.3 ± 39.3 191.5 ± 41.6 188.9 ± 36.7 183.4 ± 34.4 <0.001
 Tryglicerides (mg/dL) 160.6 ± 65.6 153.9 ± 92.8 153.5 ± 101.2 151.7 ± 129.2 0.864
 LDL cholesterol (mg/dL)‡ 121.5 ± 36.2 114.6 ± 34.9 110.6 ± 34.8 109.2 ± 32.9 0.026
 HDL cholesterol (mg/dL)†‡§|| 44.6 ± 9.2 45.4 ± 10.0 48.1 ± 11.4 48.3 ± 11.7 <0.001
 Atherogenic index†‡|| 4.6 ± 1.3 4.4 ± 1.5 4.2 ± 1.3 4.0 ± 1.2 <0.001
 Serum glucose (mg/dL) 111.4 ± 32.3 115.3 ± 43.8 112.1 ± 40.7 114.1 ± 37.4 0.759
 HbA1c (%) 6.36 ± 1.23 6.51 ± 1.34 6.51 ± 1.06 6.46 ± 1.08 0.493
 HOMA‑IR 3.2 ± 2.3 4.3 ± 10.5 2.2 ± 1.9 3.0 ± 2.2 0.284
 Office SBP (mm Hg)*‡¶ 141 ± 11 134 ± 15 138 ± 16 132 ± 16 <0.001
 Office DBP (mm Hg)*†‡||¶ 86 ± 10 81 ± 9 82 ± 10 77 ± 9 <0.001
 Mean blood pressure (mmHg)‡||¶ 101 ± 11 99 ± 10 101 ± 10 96 ± 10 <0.001
 Mean Antihypertensive drugs*†‡ 1.07 ± 1.06 1.49 ± 1.26 1.61 ± 1.32 1.64 ± 1.31 <0.001
 Antihypertensive drugs n (%)†‡ 42 (60.9) 50 (72.5) 51 (73.9) 52 (75.4) <0.001
 Mean Lipid lowering drugs†‡ 0.54 ± 0.53 0.62 ± 0.55 0.68 ± 0.61 0.68 ± 0.58 <0.001
 Lipid lowering drugs n (%)†‡ 36 (52.2) 41 (59.4) 42 (60.9) 43 (62.3) 0.048
 Mean antidiabetic drugs†‡ 0.75 ± 0.81 0.83 ± 0.82 0.91 ± 0.92 0.86 ± 0.88 0.048
 Antidiabetic drugs, n (%) 38 (55.1) 42 (60.9) 42 (60.9) 42 (60.9) 0.875
Baseline (n = 41) 1st year (n = 41) 2nd year (n = 41) 3rd year (n = 41) p
Women
 Smoker’s, n (%) 5 (12.2) 5 (12.2) 5 (12.2) 5 (12.2) 1.00
 Ischemic heart disease, n (%) 2(5) 2 (5) 3 (7) 3 (7) 0.392
 Cerebrovascular disease, n (%) 0 0 0 0 –
 BMI (kg/m2) 30.0 ± 4.1 30.3 ± 4.2 30.4 ± 4.4 30.3 ± 4.5 0.526
 Total cholesterol (mg/dL) 204.1 ± 43.8 201.2 ± 37.4 196.2 ± 26.8 188.4 ± 27.2 0.099
 Tryglicerides (mg/dL) 140.8 ± 58.7 129.9 ± 40.5 138.4 ± 61.1 129.6 ± 50.5 0.671
 LDL cholesterol (mg/dL) 121.9 ± 37.5 121.8 ± 31.1 112.8 ± 25.6 109.9 ± 24.0 0.084
 HDL cholesterol (mg/dL)†§ 51.9 ± 13.6 53.5 ± 13.6 55.8 ± 14.1 53.3 ± 11.4 0.027
 Atherogenic index 4.1 ± 1.1 3.9 ± 1.0 3.7 ± 1.1 3.7 ± 1.1 0.069
 Serum glucose (mg/dL) 116.7 ± 34.7 114.5 ± 39.3 117.4 ± 40.4 110.6 ± 28.9 0.606
 HbA1c (%) 6.37 ± 1.11 6.39 ± 1.04 6.53 ± 1.04 6.51 ± 1.04 0.220
 HOMA‑IR 3.1 ± 2.5 4.2 ± 11.6 2.9 ± 5.0 2.6 ± 2.2 0.175
 Office SBP (mm Hg) 134 ± 17 133 ± 21 131 ± 15 131 ± 17 0.738
 Office DBP (mm Hg)‡ 83 ± 12 81 ± 12 78 ± 10 77 ± 10 <0.001
 Mean Blood Pressure (mmHg) 97 ± 10 98 ± 13 97 ± 10 95 ± 11 0.260
 Mean Antihypertensive Drugs 1.46 ± 1.27 1.54 ± 1.12 1.78 ± 1.17 1.66 ± 0.94 0.133
 Antihypertensive Drugs n (%)† 29(70.7) 32 (78.0) 34 (82.9) 36 (87.8) <0.001
 Mean Lipid lowering drugs‡|| 0.56 ± 0.59 0.56 ± 0.59 0.68 ± 0.57 0.71 ± 0.56 0.017
 Lipid lowering drugs, n (%)†‡ 21 (51.2) 22 (53.7) 26 (63.4) 27 (65.9) 0.033
 Mean antidiabetic drugs† 0.95 ± 0.97 0.85 ± 0.96 1.04 ± 1.07 0.93 ± 0.96 0.108
 Antidiabetic drugs, n (%) 24 (60.9) 24 (60.9) 24 (60.9) 24 (60.9) 1.000
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glycemic control involves greater progression of PWV; 
and (5) the ABI had a negative association with the dura-
tion since diagnosis of diabetes.
We found that IMT progressed 0.005  mm annually 
in men, 0.011  mm in women and 0.018  mm in diabetic 
women. Our results are consistent with those pub-
lished by Zhao et al. [38] in diabetic women (0.022 mm/
year), but lower than the increase IMT observed in men 
(0.030 mm/year). This could be because of differences in 
age, ethnicity, BMI and the number of comorbidities. As 
in other studies with the general population [24] and dia-
betics [38], we have not found any variable that explains 
the progression of IMT in patients with insulin resist-
ance. The increase in IMT and the number of plaques 
during the follow-up period was higher in females with 
type 2 diabetes, supporting the results of previous studies 
that showed that women with diabetes have a risk of car-
diovascular events that is 2-times greater than that in 
men [12, 39].
The global annual progression of PWV in our study 
was 0.020  m/sec in men, 0.024  m/sec in women and 
0.302  m/sec in diabetic women. Our results are similar 
to those published by Marcel et  al. [25] in type 2 dia-
betic patients (the annual increase of PWV was 0.11 m/
sec) and support the data reported by De Angelis et  al. 
[40], which suggests that arterial stiffness and its progres-
sion is greater in women with type 2 diabetes mellitus. 
Similar to previous study results [25], our multivariate 
linear regression analysis showed a direct association 
between changes in PWV and mean HbA1c during fol-
low-up. These findings have important clinical implica-
tions because the improvement in glycemic control could 
Table 2 Changes in target organ damage and arterial stiffness by gender
Data for qualitative variables are expressed as n: number and (%) and quantitative variables as mean ± standard deviation
C Carotid, IMT intima media thickness carotid, ABI ankle brachial index, PWV pulse wave velocity, eGFR estimated glomerular filtration rate, Cornell VDP cornell voltage 
duration product
p < 0.05: between * baseline and 1st year; †baseline and 2nd year; ‡ baseline and 3rd year
p < 0.05: between §1st and 2nd year; ||1st and 3rd year
p < 0.05 between ¶2nd and 3rd year
Men Baseline (n = 71) 1st year (n = 69) 2nd year (n = 69) 3rd year (n = 69) p
Vascular
 C‑IMT average (mm)¶ 0.779 ± 0.127 0.776 ± 0.123 0.769 ± 0.123 0.796 ± 0.126 0.005
 Plaques carotid n (%) 16 (23.2) 15 (21.7) 19 (27.5) 21 (30.4) 0.148
 ABI* 1.15 ± 0.11 1.19 ± 0.12 1.18 ± 0.13 1.16 ± 0.11 <0.001
 PWV (m/s) 9.31 ± 2.32 9.33 ± 2.64 9.68 ± 2.37 9.48 ± 2.47 0.661
Renal
 Serum creatinine (mg/dL) 0.95 ± 0.14 0.97 ± 0.18 0.93 ± 0.17 0.96 ± 0.18 0.110
 eGFR (mL/min/1.73 m2) 89.5 ± 16.8 88.5 ± 18.3 92.3 ± 19.8 87.9 ± 18.2 0.072
 Albumin/creatinine ratio (mg/g) 34.8 ± 81.4 44.0 ± 122.9 37.7 ± 113.8 45.9 ± 156.8 0.826
Heart
 Cornell VDP (mm/ms) 1487 ± 573 1538 ± 506 1515 ± 543 1458 ± 535 0.285
 Sokolow (mm/ms)*§|| 20.3 ± 5.9 18.7 ± 6.2 21.3 ± 6.6 20.4 ± 6.8 <0.001
Women Baseline (n = 41) 1st year (n = 41) 2nd year (n = 41) 3rd year (n = 41) p
Vascular
 C‑MT average (mm)§ 0.715 ± 0.092 0.728 ± 0.076 0.726 ± 0.099 0.754 ± 0.115 0.034
 Plaques carotid, n (%)†§ 3 (7.3) 3 (7.3) 6 (14.6) 11 (26.8) <0.001
 ABI*†‡ 1.07 ± 0.10 1.17 ± 0.09 1.18 ± 0.10 1.14 ± 0.09 <0.001
 PWV (m/s) 9.74 ± 2.70 9.21 ± 2.11 9.14 ± 2.34 9.79 ± 2.92 0.286
Renal
 Serum creatinine (mg/dL) 0.73 ± 0.11 0.73 ± 0.12 0.70 ± 0.13 0.72 ± 0.14 0.285
 eGFR (mL/min/1.73 m2) 89.1 ± 16.6 93.2 ± 22.6 95.0 ± 16.6 93.1 ± 22.1 0.163
 Albumin/creatinine ratio (mg/g) 14.6 ± 37.4 6.6 ± 6.6 3.0 ± 5.6 9.1 ± 14.8 0.122
Heart
 Cornell VDP (mm/ms) 1741 ± 598 1756 ± 542 1852 ± 680 1838 ± 740 0.430
 Sokolow (mm/ms)§ 19.1 ± 6.1 19.4 ± 5.3 20.5 ± 5.6 19.6 ± 5.7 0.013
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reduce aortic stiffness, thus reducing the burden of mor-
bidity and mortality associated with type 2 diabetes.
We also found a negative association between age, BMI 
and eGFR, which is in line with previously-published 
results in patients with type 2 diabetes mellitus [26, 41]. 
The trend for the ABI was similar in both sexes, for the 
absolute values and the percentage of patients with 
ABI < 0.9.
The evaluation of left ventricular hypertrophy was 
based on the Sokolow criteria and it showed differences 
between the four measurements in both sexes. However, 
the results did not show a clear trend, and there was no 
variable explaining these changes [13].
In summary, our results were similar to previously-
published results [12, 42], indicating that women with 
type 2 diabetes are more vulnerable than men to develop 
vascular and renal TOD in the pre-occurrence phases of 
cardiovascular disease.
The poorer evolution of vascular and renal TOD in 
females, particularly among those with diabetes, may be 
due to the fact that women show greater stiffness values 
in the prepubertal period, and this stiffness moreover 
increases after menopause. This suggests that women 
intrinsically have stiffer large arteries than men—though 
these effects are mitigated by the sexual steroids during 
the reproductive years [43, 44]. Other factors that can 
influence the gender differences are: the sexual dimor-
phism of lipid metabolism, these differences include how 
dietary fatty acids are handled, the secretion and clear-
ance of very low-density lipoprotein-triglycerides, the 
release rates of free fatty acids from adipose tissue rela-
tive to energy needs, and the removal of free fatty acids 
Table 3 Changes in target organ damage by gender
Data for qualitative variables are expressed as n: number and (%) and quantitative variables as mean ± standard deviation
Y year, C carotid, IMT intima media thickness carotid, ABI ankle brachial index, PWV pulse wave velocity, eGFR estimated glomerular filtration rate, Cornell VDP cornell 
voltage duration product, p gender differences
Global Men Women p
n = 112 n = 61 n = 41
Vascular
 C IMT average baseline (mm) 0.775 ± 0.121 0.779 ± 0.127 0.715 ± 0.092 0.003
 C IMT average final (mm) 0.780 ± 0.123 0.796 ± 0.126 0.754 ± 0.115 0.084
 Difference (final–baseline) 0.025 ± 0.077 0.017 ± 0.070 0.039 ± 0.087 0.147
 Annual increase 0.007 ± 0.023 0.005 ± 0.021 0.011 ± 0.025 0.215
 Annual increase in diabetic patients 0.011 ± 0.002 0.007 ± 0.022 0.018 ± 0.027 0.021
 ABI baseline 1.129 ± 0.121 1.116 ± 0.120 1.080 ± 0.109 0.001
 ABI final 1.179 ± 0.107 1.190 ± 0.11 1.160 ± 0.09 0.128
 Difference (final–baseline) 0.049 ± 0.148 0.033 ± 0.155 0.076 ± 0.135 0.142
 Annual increase 0.015 ± 0.044 0.010 ± 0.045 0.022 ± 0.021 0.157
 Annual increase in diabetic patients 0.011 ± 0.042 0.004 ± 0.671 0.021 ± 0.512 0.157
 PWV baseline (m/sec) 9.470 ± 2.467 9.310 ± 2.324 9.740 ± 2.695 0.393
 PWV final (m/sec) 9.594 ± 2.643 9.476 ± 2.472 9.788 ± 2.922 0.507
 Difference (final–baseline) 0.108 ± 2.255 0.146 ± 2.029 0.046 ± 2.603 0.551
 Annual increase 0.022 ± 0.672 0.020 ± 0.58 0.024 ± 0.80 0.835
 Annual increase in diabetic patients 0.178 ± 0.632 0.098 ± 0.512 0.302 ± 0.780 0.003
Renal
 eGFR baseline (mL/min/1.73 m2) 89.383 ± 16.658 89.542 ± 16.810 89.115 ± 18.190 0.897
 eGFR final (mL/min/1.73 m2) 89.898 ± 18.834 87.891 ± 18.19 93.129 ± 22.07 0.207
 Difference (final–baseline) −1.341 ± 20.100 −2.349 ± 21.253 4.015 ± 16.917 0.022
 Annual increase −0.170 ± 4.945 −0.732 ± 4.698 1.184 ± 5.218 0.104
 Annual increase in diabetic patients −0.308 ± 5.095 −1.286 ± 5.301 1.257 ± 4.406 0.052
Heart
 Cornell VDP baseline (mm/ms) 1604 ± 645 1487 ± 573 1741 ± 598 0.032
 Cornell VDP final (mm/ms) 1568 ± 594 1458 ± 535 1838 ± 740 0.006
 Difference (final–baseline) 36 ± 371 −31 ± 291 97 ± 471 0.229
 Annual increase 12 ± 111 −9 ± 29 31 ± 141 0.206
 Annual increase in diabetic patients 6 ± 101 −8 ± 76 29 ± 131 0.430
Page 8 of 11Gómez‑Marcos et al. Cardiovasc Diabetol  (2015) 14:132 
from the circulation, including the storage of free fatty 
acids into adipose tissue via the direct uptake process [45, 
46] and inflammatory factors [47].
The results of this study will help medical professionals 
in their routine practice to consider gender differences, 
particularly as regards the group of diabetic women, with 
a view to performing better evaluation of vascular, renal 
and cardiac TOD, and thus affording better treatment 
suited to each individual case.
This study has some limitations that must be consid-
ered. First, the small number of subjects per group lim-
its the power of analysis. Second, creatine albumin index 
was determined in a single sample each year. Also, at the 
time of viewing these results, the subjects included in the 
study had multiple associated pathologies and were being 
treated with many drugs, which may have affected the 
TOD values. It is also limited to 3.5  years of follow-up. 
In addition, these patients were not randomized but were 
involved consecutive sampling.
In conclusion, this study showed that the progression 
of vascular and renal TOD differs by gender. The increase 
of vascular and renal TOD was higher in women, espe-
cially in diabetic women. The increase in PWV showed 
a positive association with mean HbA1c in the follow-up 
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Fig. 2 Changes in target organ damage over time during 3.5 years of follow‑up. a Target organ damage (TOD) in men and in women; b Vascular 
TOD in men and in women. IMT intima media thickness, cf-PWV carotid femoral pulse wave velocity, ABI ankle brachial index. In men, the vascular 
TOD was significantly different between the final and baseline assessment and the 2nd and 3rd assessments (p < 0.05). The cf‑PWV TOD was also 
significantly different between the final and baseline assessment (p < 0.05). In women, the vascular TOD was significantly different between the 2nd 
and 3rd assessments (p < 0.05). There was also a significant difference in the IMT TOD between the baseline and 2nd assessment and between the 
2nd and 3rd assessment (p < 0.05). The cf‑PWV TOD was significantly different between the 2nd and 3rd assessment (p < 0.05)
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period. Glomerular filtration was associated with BMI 
and the ABI was associated with duration since type 2 
diabetes mellitus diagnosis.
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